



United States Patent and Trademark Office





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/599,158	06/21/2000	Jacob Richter	2390/47503	6935	
26646	7590 08/15/2002				
KENYON & KENYON			EXAMINER		
ONE BROAD NEW YORK,			BLANCO, JAVIER G		
			ART UNIT	PAPER NUMBER	
			3738		
			DATE MAILED: 08/15/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

	_				ale			
		Application No		Applicant(s)	- UV			
,	,	09/599,158		RICHTER, JACOB				
	Office Action Summary	Examiner		Art Unit				
		Javier G. Blanco	,	3738				
Period fo	The MAILING DATE of this communication or Reply	appears on the cove	r sheet with the c	orrespondence ad	dress			
THE I - Externance - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REMAILING DATE OF THIS COMMUNICATION asions of time may be available under the provisions of 37 CF SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by seply received by the Office later than three months after the red patent term adjustment. See 37 CFR 1.704(b).	ON. R 1.136(a). In no event, hown, a reply within the statutory mieriod will apply and will expire statute, cause the application	ever, may a reply be tim nimum of thirty (30) days SIX (6) MONTHS from to become ABANDONEI	ely filed s will be considered timely the mailing date of this co O (35 U.S.C. § 133).				
1)⊠	Responsive to communication(s) filed on	<u>31 July 2002</u> .						
2a)	This action is FINAL . 2b)	This action is non-f	inal.					
3) Dispositi	Since this application is in condition for al closed in accordance with the practice un on of Claims				e merits is			
4)🖂	Claim(s) 48 and 51-57 is/are pending in the	ne application.						
4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	Claim(s) is/are allowed.							
6)⊠	Claim(s) 48 and 51-57 is/are rejected.							
7)	Claim(s) is/are objected to.							
	Claim(s) are subject to restriction an on Papers	nd/or election require	ment.					
_	Γhe specification is objected to by the Exan	niner.						
	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority u	nder 35 U.S.C. §§ 119 and 120							
13)	Acknowledgment is made of a claim for for	eign priority under 3	5 U.S.C. § 119(a)	-(d) or (f).				
a)[☐ All b)☐ Some * c)☐ None of:							
	1. Certified copies of the priority docum	nents have been rece	eived.					
	2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
	cknowledgment is made of a claim for dom		•		application).			
_ a)	The translation of the foreign language	provisional applicati	on has been rece	eived.	.,			
Attachment	-	,	00					
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948 nation Disclosure Statement(s) (PTO-1449) Paper No			(PTO-413) Paper No(satent Application (PTC				
J.S. Patent and Tr PTO-326 (Rev		ce Action Summary		Part of	Paper No. 8			

Application/Control Number: 09/599,158 Page 2

Art Unit: 3738

DETAILED ACTION

Drawings

1. This application has been filed with informal drawings which are acceptable for examination purposes only. Formal drawings will be required when the application is allowed.

Claim Rejections - 35 USC § 112

- 2. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 3. Claims 48 and 51-53 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 48, a "lumen having a non-uniform radial force" (see lines 1-2) was not disclosed/described in the specification.

Double Patenting

- 4. Claims 48 and 51-57 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 5,807,404.

 Although the conflicting claims are not identical, they are not patentably distinct from each other because:
- a. Claims 1-28 teaches that in order to exert a non-uniform radial force at either the distal portion (= distal row) of a stent, or the distal and proximal portions of a stent, a reduction of the length of

Application/Control Number: 09/599,158

Art Unit: 3738

some of the sections at the distal end or distal/proximal ends, and the use of a more flexible material, is what is needed.

b. The difference between claims 48 and 51-57 of the application and claims 1-28 of the patent lies in the fact that the patent claims includes more elements and is thus much more specific. Thus the invention of claims 1-28 is in effect a "species" of the "generic" invention of claims 48 and 51-57. It has been held that the generic invention is "anticipated" by the "species". See *In re Goodman*, 29 USPQ2d 2010 (Fed. Cir. 1993). Since claims 48 and 51-57 are anticipated by claims 1-28 of the patent, it is not patentably distinct from claims 1-28.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Application/Control Number: 09/599,158

Art Unit: 3738

To the same of the same of the same

- 6. Claims 48 and 51-57 are rejected under 35 U.S.C. 102(b) as being anticipated by Simon et al. (US 5,354,308). Simon et al. disclose an expandable stent comprising a plurality of interconnected cells, wherein the cells disposed at the ends of the stent are adapted to exert greater radial force and are more flexible than the cells at the center of the stent (see column 3, lines 40-42 and lines 51-56; column 5, lines 23-32; Figures 1, 4, and 8B).
- 7. Claims 48 and 51-57 are rejected under 35 U.S.C. 102(e) as being anticipated by Kleshinski et al. (US 5,902,317). Kleshinski et al. disclose an expandable stent comprising a plurality of interconnected flexible cells (see Figures 1, 4, and 10). The stent could be adapted or modified to have different sized cells and/or use different wire sizes to exert greater radial forces (and increase flexibility) for treating a lumen having a non-uniform diameter, a non-uniform radial force, or a non-uniform longitudinal flexibility (see Abstract; column 7, lines 34-57; column 8, lines 28-33; claims 1 and 2).

Conclusion

8. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Pinchasik et al. (US 5,449,373 A), Israel et al. (US 5,733,303 A), Jang (US 5,954,743 A), Penn et al. (US 6,375,677 B1), Hassdenteufel (US 6,416,539 B1), Vallana et al. (Pub. No.: US 2001/0044649 A1), and White et al. (Pub. No.: US 2002/0065549 A1).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Javier G. Blanco whose telephone number is 703-605-4259. The examiner can normally be reached on M-F (7:00 a.m.-4:30 p.m.), first Friday off.

Application/Control Number: 09/599,158

Art Unit: 3738

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on 703-308-2111. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9302 for regular communications and 703-872-9303 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0858.

JGB

August 8, 2002

Page 5

Primary Examiner